智通财经APP获悉，摩根士丹利分析师Terence Flynn发表研报，重申吉利德科学(GILD.US)“买入”评级，并将目标价定为143美元。
该分析师指出，美国疾病控制与预防中心(CDC)近期已将吉利德的Yeztugo药物纳入艾滋病(HIV)暴露前预防推荐用药。Flynn认为，这一推荐是对该药物疗效与安全性的权威认可。此外，他还表示，CDC的推荐有望提升患者用药依从性，强化HIV预防效果，进而推动Yeztugo的市场需求增长。
与此同时，吉利德科学正积极推进Yeztugo的商业保险覆盖计划，预计到2025年底，该药物将获得大范围的保险报销支持。
作为一家生物制药企业，吉利德科学专注于研发治疗重大疾病的药物，其研发领域涵盖HIV、病毒性肝炎、新型冠状病毒肺炎(COVID-19)及癌症等。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.